Novartis Just Spent $925M on a Drug That Can't Beat the Reigning Champ

The Eliquis Problem

To understand why this matters, you need to appreciate just how dominant Eliquis has become. It's less a drug and more a force of nature.

In 2024, Eliquis generated approximately $13.3 billion in revenue for Bristol Myers Squibb alone (Pfizer books its own share separately). That figure accounted for roughly 27.5% of BMS's entire revenue, making it the company's single most important product. For context, it outsold Opdivo, BMS's blockbuster cancer immunotherapy, by more than $5 billion.

And it's still growing. BMS projects 10 to 15% revenue growth for Eliquis in 2026, which could push worldwide sales north of $16 billion. Trying to compete against a drug with that kind of clinical track record and market momentum is like challenging a Formula 1 car to a drag race in a Honda Civic. Your car might be perfectly fine; it's just not winning that particular race.

Not Dead, Just Narrower

Before you write abelacimab's obituary, know this: Novartis isn't abandoning the drug entirely. The company is refocusing on its lead indication, atrial fibrillation (AFib), where a phase 3 trial called LILAC-TIMI 76 is still running. AFib is a heart rhythm disorder that affects millions of people worldwide, and patients typically need blood thinners for years (sometimes decades) to prevent strokes.

That's where the bleeding safety advantage could really shine. Current anticoagulants work well at preventing strokes, but their bleeding side effects are a persistent headache for doctors and patients alike. Studies suggest that 12 to 16% of patients on standard anticoagulants experience bleeding complications over two years. If abelacimab can match the stroke prevention of Eliquis while dramatically cutting bleeding risk, it would have a compelling case.

That's a long runway, but AFib is a far larger market than cancer-associated thrombosis. The strategic pivot makes financial sense, even if it stings.

Everyone Else Is Trying Too

Novartis isn't alone in chasing the Factor XIa dream. The competitive landscape looks like a crowded marathon where everyone keeps tripping.

Bayer's asundexian hit a speed bump in 2024 when it failed a non-inferiority test against Eliquis (again, that drug). But it did show roughly 70% reduced bleeding, enough to keep the program alive. Johnson & Johnson's milvexian is further along, currently in phase 3 trials for AFib under the name LIBREXIA-AF.

The pattern is telling. Factor XIa inhibitors consistently show they're safer in terms of bleeding. The challenge is proving they prevent clots just as well as the drugs already on the market. It's the classic innovator's dilemma: you need to be at least as good at the main job while being better at the side effects. That's a high bar when the incumbent is a $14 billion product with years of real-world data behind it.

Novartis's Bigger Cardiovascular Bet

Despite this setback, Novartis hasn't lost faith in heart medicine. Cardiovascular, renal, and metabolic diseases remain one of the company's four core therapeutic areas, alongside oncology, immunology, and neuroscience.

Entresto, its heart failure drug, pulled in $7.8 billion in 2024 sales with 31% growth. And Novartis recently signed a $1.8 billion collaboration with Unnatural Products to develop cardiovascular drugs targeting proteins that were previously considered undruggable. The Anthos reacquisition and abelacimab setback are a chapter, not the whole story.

The Takeaway

Novartis spent nearly a billion dollars to bring abelacimab back in-house, and within a year, it had to scale back the program's ambitions. That's not a failure of science; it's a reminder of how brutally competitive the anticoagulant market has become. Eliquis isn't just a successful drug. It's a moat, a fortress, and a warning sign to anyone who thinks they can waltz in without something truly differentiated.

The AFib bet is still live, and if abelacimab can deliver on its bleeding safety promise in that indication, the story could look very different by 2028. But for now, Novartis learned an expensive lesson that plenty of pharma companies already knew: beating Eliquis requires more than a good idea. It requires a better result.

The Gene Therapy That's Making Deaf People Hear Whispers

A gene therapy trial just restored hearing in 90% of deaf patients, some within weeks of a single injection. The results are 'mind-boggling,' and pharma companies are spending billions to win the race.